Pfizer releases more positive data for COVID-19 oral antiviral

Dec 14, 2021 - 11:53 AM
COVID19 Web Sized

Pfizer today announced additional phase 2/3 clinical trial data for its COVID-19 oral antiviral treatment, indicating the pill’s high degree of effectiveness in reducing high-risk patients’ risks of hospitalization or death from SARS-CoV-2 infection. Pfizer said that, among high-risk patients, the antiviral reduced risk of hospitalization or death by 89% when taken within three days of symptoms’ onset, with a similar effectiveness — 88% — when administered within five days of symptoms. Interim results from an ongoing study of standard-risk adults indicate a 70% reduction in hospitalizations, with zero deaths. Pfizer also released in vitro data indicating that the drug would maintain its effectiveness against omicron and future SARS-CoV-2 variants. 

Related News Articles

Headline
View the AHA's latest United Against the Flu toolkit celebrating fall
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
CDC recommends two doses of COVID-19 vaccine for older individuals, lowers pneumococcal vaccine age 
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
CDC reminds hospital and health system workers to protect themselves, patients during respiratory virus season
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Chair File: The Best Defense Against Flu and COVID-19
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
Survey: Less than 20% of U.S. adults concerned for themselves or family receiving infection ahead of respiratory virus season
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
FDA authorizes combination tests for flu, COVID-19
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…